Menu Search
Equities

Universal Ibogaine Inc

JC4:BER

Universal Ibogaine Inc

Actions
  • Price (EUR)0.014
  • Today's Change0.001 / 3.70%
  • Shares traded20.00k
  • 1 Year change+3.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 13:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The Company is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. It is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.

  • Revenue in CAD (TTM)2.33m
  • Net income in CAD-1.56m
  • Incorporated2017
  • Employees--
  • Location
    Universal Ibogaine Inc(c/o Suite 600 - 815 8th Avenue SWCALGARY T2P 3P2CanadaCAN
  • Phone+1 (403) 870-1841
  • Fax+1 (403) 870-1841
  • Websitehttps://universalibogaine.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.